Clinical Trials
34 trialsNCT07458347 2026-06-15
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Kestrel Therapeutics, Inc.
Phase 1 Recruiting
NCT03801083 2026-06-01
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
University of Pittsburgh
Phase 2 Active not recruiting
NCT07619235 2026-06-01
A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract Cancer
Huazhong University of Science and Technology
Phase 4 Not yet recruiting
NCT07614061 2026-05-29
Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
Shanghai Zhongshan Hospital
Phase 1 Recruiting
NCT07608458 2026-05-27
Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy
City of Hope Medical Center
Phase NA Not yet recruiting
NCT06937567 2026-05-26
CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
Zhejiang University
Phase EARLY_PHASE1 Recruiting
NCT07599995 2026-05-20
GENE
Sir Run Run Shaw Hospital
Phase 2 Not yet recruiting
NCT05615818 2026-05-19
SAFIR-ABC10
UNICANCER
Phase 3 Recruiting
NCT06529718 2026-05-19
SEVILLA
UNICANCER
Phase 2 Recruiting
NCT04776837 2026-05-15
Predicting Disease Progression and/or Recurrence in Cancer
Massachusetts General Hospital
Completed
NCT06564623 2026-05-08
Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Recruiting
NCT07466238 2026-05-08
HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer
Peking University
Phase NA Recruiting
NCT05220046 2026-05-06
Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers
University of Nebraska
Phase 1 Active not recruiting
NCT06375967 2026-05-06
CARPEGIEM
Hospital Universitari de Bellvitge
Phase NA Suspended
NCT06653192 2026-05-06
EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction (CARPEDIEM Trial)
Hospital Universitari de Bellvitge
Phase NA Suspended
NCT07569679 2026-05-06
Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract Cancer
Air Force Military Medical University, China
Phase 2 Recruiting
NCT02908048 2026-05-05
Extracellular RNA Markers of Liver Disease and Cancer
Mayo Clinic
Terminated
NCT03482102 2026-05-04
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT07030140 2026-05-01
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT07561775 2026-05-01
Adebrelimab Plus S-1 for Resected Cholangiocarcinoma
Tongji Hospital
Phase 2 Not yet recruiting
NCT07206355 2026-04-29
Map HPB
University of Nottingham
Recruiting
NCT03631173 2026-04-28
MINIMUM
Oslo University Hospital
Phase NA Active not recruiting
NCT07532759 2026-04-16
Impact of Intraoperative PTCD Catheter Retention Versus Removal on Postoperative Short-term Outcomes After Pancreaticoduodenectomy in Obstructive Jaundice
Fudan University
Phase NA Not yet recruiting
NCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT07530445 2026-04-15
Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Sun Yat-sen University
Phase 2 Recruiting
NCT03406299 2026-04-09
Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT07515950 2026-04-07
REVEAL-BTC
MedSIR
Not yet recruiting
NCT07319767 2026-04-06
Comparing the TDTP-RECIST With RECIST 1.1 and Other Volumetric Evaluation Methods for Assessing the Therapeutic Efficacy of Irregular Malignant Tumors
Shanghai Zhongshan Hospital
Completed
NCT07107750 2026-04-03
Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer
Washington University School of Medicine
Phase 1 Recruiting
NCT07506057 2026-04-01
SHIELD
China Medical University, China
Phase 2 Recruiting
NCT06178445 2026-03-27
TRAP-BTC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT06648057 2026-03-18
Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
CHA University
Recruiting
NCT07142226 2026-03-18
Role of ctDNA in Genetic Profiling & Outcomes for Advanced BTC
CHA University
Recruiting
NCT07151118 2026-03-18
ctDNA in Genetic Profiling and Clinical Outcomes of Advanced Biliary Tract Cancer
CHA University
Recruiting